Sign up
Pharma Capital

Arix Bioscience confirms Autolus to launch proposed public offering

The final price has not yet been set but Autolus is planning on issuing up to 4.6mln American Depositary Shares (ADS) as part of the offering
Nasdaq
Autolus was spun out from University College London in 2014

Biotech investor Arix Bioscience PLC (LON:ARIX) has confirmed that its investee company, Autolus Therapeutics PLC (NASDAQ:AUTL), has announced the launch of a proposed public offering in the United States.

The proposed maximum aggregate offering amount specified in the filing is 4mln American Depositary Shares (ADS), which does not include the underwriters’ option to purchase 600,000 additional ADS.

Each ADS represents one ordinary share. The final price per ADS in the offering will be determined following a book building process.

Arix shares were unchanged on Tuesday at 143p.

View full ARIX profile View Profile
View All

Related Articles

© biotech Capital 2019

Biotech Capital, a subsidiary of Proactive Investors, acts as the vanguard for listed biotech companies to interact with institutional and highly capitalised investors.
Headquartered in London, Biotech Capital is led by a team of Europe's leading analysts and journalists, publishing daily content, covering all key movements in the Biotechnology market.